What amount sold does Thrombolex, Inc. report in Form D filings?

The latest linked filings report $55.6M sold across 6 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Thrombolex, Inc.'s most recent SEC filing?

Thrombolex, Inc.'s most recent Form D filing was on 2026-03-12.

How many investors does Thrombolex, Inc. have?

The most recent Form D filing lists 22 investor(s).

What type of securities does Thrombolex, Inc. offer?

Thrombolex, Inc.'s SEC Form D filings indicate equity offerings.

Thrombolex, Inc.

CIK: 0001703764·Other Health Care·Kingston, NJ·Corporation

Reported Sold

$55,631,251

Total Filings

Identified Offerings

Last Filed

Mar 12, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Other Health Care industry

SEC EDGAR

Offering filing timeline

Mar 12, 2026Form D — New notice

Reported sold: $32,775,000 · Target: $51,105,000

Rule 506(b)·22 investors

Jun 21, 2024Form D — New notice

Reported sold: $1,160,000 · Target: $5,000,000

Rule 506(b)·5 investors

May 28, 2024Form D — New notice

Reported sold: $4,839,829 · Target: $4,839,829

Rule 506(b)·56 investors

Aug 30, 2022Form D — New notice

Reported sold: $2,015,761 · Target: $2,015,761

Rule 506(b)·50 investors

Nov 29, 2021Form D — New notice

Reported sold: $5,020,779 · Target: $5,020,779

Rule 506(b)·46 investors

Feb 3, 2020Form D/A — Amendment

Reported sold: $9,819,882 · Target: Indefinite

Rule 506(b)·33 investors

Changed: Reported amount sold, Reported investors

Apr 17, 2018Form D/A — Amendment

Reported sold: $3,540,000 · Target: Indefinite

Rule 506(b)·19 investors

Changed: Reported amount sold, Offering target, Reported investors, Reported revenue range

Apr 17, 2017Form D — New notice

Reported sold: $400,000 · Target: $1,500,000

Rule 506(b)·1 investor

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

25%

Latest reported sold across 6 identified offerings

$55,631,251

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Michael J. Cerminaro

Related Person

Appears on 7 filings

Marvin Woodall

Related Person

Appears on 5 filings

John Cerminaro

Related Person

Appears on 5 filings

Paul A. Stewart

Related Person

Appears on 5 filings

Todd Richmond

Related Person

Appears on 4 filings

Kelly Elliott

Related Person

Appears on 2 filings

Tony Litwiller

Related Person

Appears on 2 filings

Marvin Woodall

Related Person

Appears on 2 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Mar 12, 2026	New	$51,105,000	$32,775,000	22
Jun 21, 2024	New	$5,000,000	$1,160,000	5
May 28, 2024	New	$4,839,829	$4,839,829	56
Aug 30, 2022	New	$2,015,761	$2,015,761	50
Nov 29, 2021	New	$5,020,779	$5,020,779	46
Feb 3, 2020	Amendment	Indefinite	$9,819,882	33
Apr 17, 2018	Amendment	Indefinite	$3,540,000	19
Apr 17, 2017	New	$1,500,000	$400,000	1

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Onkos Surgical, Inc.

Other Health Care

Offering target: $37,245,260

Filed Aug 7, 2026